Candace Lemke
Family · Fort Wayne, INNPI 1043446776
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 308 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 308 payments — averaging $17.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$1K
- Corium, LLC$870
- E.r. Squibb & Sons, L.L.C.$533
- Otsuka America Pharmaceutical, Inc.$504
- Supernus Pharmaceuticals, Inc.$423
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$362
- plus $2K from 12 others
What the payments were for
- Food & beverage$5,18097%
- Education$1793%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 52 | $1,063 |
| Corium, LLC | 69 | $870 |
| E.r. Squibb & Sons, L.L.C. | 52 | $533 |
| Otsuka America Pharmaceutical, Inc. | 10 | $504 |
| Supernus Pharmaceuticals, Inc. | 24 | $423 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $362 |
| Teva Pharmaceuticals USA, Inc. | 8 | $271 |
| AbbVie | 18 | $237 |
| Lundbeck LLC | 13 | $221 |
| Tris Pharma Inc | 10 | $196 |
| Alkermes, Inc. | 9 | $180 |
| Biogen | 8 | $144 |
| Indivior Inc. | 6 | $114 |
| Axsome Therapeutics, Inc. | 4 | $93 |
| Johnson & Johnson | 3 | $70 |
| Ironshore Pharmaceuticals Inc. | 2 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Almatica Pharma LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$122
- ABILIFY MAINTENA$122
How this compares
$5,360 in reported general payments places this provider in the 90th percentile of 4,392 family providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 26 | $282,415 |
| Invega SustennaPaliperidone Palmitate | 70 | $211,441 |
| VraylarCariprazine Hcl | 111 | $164,878 |
| IngrezzaValbenazine Tosylate | 19 | $147,144 |
| RexultiBrexpiprazole | 96 | $144,944 |
| CaplytaLumateperone Tosylate | 76 | $126,311 |
| Austedo XrDeutetrabenazine | 15 | $94,312 |
| TrintellixVortioxetine Hydrobromide | 120 | $69,253 |
| Abilify MaintenaAripiprazole | 28 | $65,181 |
| FanaptIloperidone | 15 | $25,913 |
| NuedextaDextromethorphan Hbr/Quinidine | 11 | $20,076 |
| LybalviOlanzapine/Samidorphan Malate | 12 | $19,065 |
| Paliperidone ErPaliperidone | 56 | $18,213 |
| FetzimaLevomilnacipran Hcl | 26 | $15,130 |
| Aripiprazole | 198 | $13,188 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $271 | $376,72841 claims |
| Johnson & JohnsonInvega Sustenna | $70 | $211,44170 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $504 | $210,125124 claims |
| AbbVieVraylar, Fetzima | $237 | $180,008137 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $362 | $126,31176 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $18 | $69,253120 claims |
| Alkermes, Inc.Lybalvi | $180 | $19,06512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,392 family providers in Indiana.
Other family in Fort Wayne
- Justin BrownFort Wayne$142K
- Tracy JohnsonFort Wayne$68K
- Grant BlauveltFort Wayne$28K
- Benjamin GiarmoFort Wayne$21K
- Katarzyna SedlaczekFort Wayne$20K
- Brandy DantzerFort Wayne$18K
- Catherine RobertsFort Wayne$13K
- Adam ZuberFort Wayne$13K
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.